Cite

HARVARD Citation

    Gros, B. et al. (2023). Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort. United European Gastroenterology journal. 11 (2), pp. 179-188. [Online]. 
  
Back to record